CX1739

CX1739
临床资料
其他名称	CX-1739
法律规范状态
法律规范	美：Investigational New Drug;
识别信息
	IUPAC命名法 N-methyl-N-(oxan-4-yl)-2,1,3-benzoxadiazole-5-carboxamide; ;
CAS号	1086377-48-1
PubChem CID	25104045;
ChemSpider	103868867;
UNII	UPB5G360MA;
化学信息
化学式	C13H15N3O3
摩尔质量	261.28 g·mol−1
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES CN(C1CCOCC1)C(=O)C2=CC3=NON=C3C=C2;
	InChI InChI=1S/C13H15N3O3/c1-16(10-4-6-18-7-5-10)13(17)9-2-3-11-12(8-9)15-19-14-11/h2-3,8,10H,4-7H2,1H3; Key:IRYRMRDDVXULFG-UHFFFAOYSA-N;

CX1739是一种由Cortex药业（现为RespireRx）开发的研究性新药，目前正在评估其用于治疗多种疾病，例如注意力不足过动症^[1]、自闭症^[2]、阿片引发的呼吸抑制^[3]^[4]及中枢神经性睡眠呼吸暂停（英语：Central sleep apnea）。^[5]

合成

CX1739可由可由苯并呋咱-5-甲酸和N-甲基四氢吡喃-4-胺反应制得。^[6]

参考文献

^ Radin DP, Lippa A, Rana S, Fuller DD, Smith JL, Cerne R, Witkin JM. Amplification of the therapeutic potential of AMPA receptor potentiators from the nootropic era to today. Pharmacology, Biochemistry, and Behavior. 2025, 248: 173967. PMC 11849398 . PMID 39894310. doi:10.1016/j.pbb.2025.173967. 已忽略未知参数|pmc-embargo-date= (帮助)
^ Silverman J, Oliver C, Karras M, Gastrell P, Crawley J. AMPAKINE enhancement of social interaction in the BTBR mouse model of autism. Neuropharmacology. 2013, 64 (1): 268–282. PMC 3445667 . PMID 22801296. doi:10.1016/j.neuropharm.2012.07.013.
^ Radin DP, Zhong S, Cerne R, Shoaib M, Witkin JM, Lippa A. Low-Impact Ampakine CX1739 Exerts Pro-Cognitive Effects and Reverses Opiate-Induced Respiratory Depression in Rodents. Future Pharmacology. 2024, 4: 173–187. doi:10.3390/futurepharmacol4010012 .
^ Xiao D, Xie F, Xu X, Zhou X. The Impact and Mechanism of Ampakine CX1739 on Protection Against Respiratory Depression in Rats. Future Medicinal Chemistry. 2020, 12 (23): 2093–2104. PMID 33030058. doi:10.4155/fmc-2020-0256.
^ Ren J, Ding X, Greer JJ. Ampakines Enhance Weak Endogenous Respiratory Drive and Alleviate Apnea in Perinatal Rats. American Journal of Respiratory and Critical Care Medicine. 2015, 191 (6): 704–710. PMID 25594679. doi:10.1164/rccm.201410-1898OC.
^ Xiao, Dian; et al. The impact and mechanism of ampakine CX1739 on protection against respiratory depression in rats. Future Medicinal Chemistry (2020), 12(23), 2093-2104. doi:10.4155/fmc-2020-0256.

[Radin_2025-1] Radin DP, Lippa A, Rana S, Fuller DD, Smith JL, Cerne R, Witkin JM. Amplification of the therapeutic potential of AMPA receptor potentiators from the nootropic era to today. Pharmacology, Biochemistry, and Behavior. 2025, 248: 173967. PMC 11849398 . PMID 39894310. doi:10.1016/j.pbb.2025.173967. 已忽略未知参数|pmc-embargo-date= (帮助)

[Silverman_2013-2] Silverman J, Oliver C, Karras M, Gastrell P, Crawley J. AMPAKINE enhancement of social interaction in the BTBR mouse model of autism. Neuropharmacology. 2013, 64 (1): 268–282. PMC 3445667 . PMID 22801296. doi:10.1016/j.neuropharm.2012.07.013.

[Radin_2024-3] Radin DP, Zhong S, Cerne R, Shoaib M, Witkin JM, Lippa A. Low-Impact Ampakine CX1739 Exerts Pro-Cognitive Effects and Reverses Opiate-Induced Respiratory Depression in Rodents. Future Pharmacology. 2024, 4: 173–187. doi:10.3390/futurepharmacol4010012 .

[Xiao_2020-4] Xiao D, Xie F, Xu X, Zhou X. The Impact and Mechanism of Ampakine CX1739 on Protection Against Respiratory Depression in Rats. Future Medicinal Chemistry. 2020, 12 (23): 2093–2104. PMID 33030058. doi:10.4155/fmc-2020-0256.

[Ren_2015-5] Ren J, Ding X, Greer JJ. Ampakines Enhance Weak Endogenous Respiratory Drive and Alleviate Apnea in Perinatal Rats. American Journal of Respiratory and Critical Care Medicine. 2015, 191 (6): 704–710. PMID 25594679. doi:10.1164/rccm.201410-1898OC.

[6] Xiao, Dian; et al. The impact and mechanism of ampakine CX1739 on protection against respiratory depression in rats. Future Medicinal Chemistry (2020), 12(23), 2093-2104. doi:10.4155/fmc-2020-0256.

[1]

[2]

[3]

[4]

[5]

[6]